MRK | Merck & Co., Inc.

Healthcare | Drug Manufacturers - General | USA | NYSE

Index	DJIA, S&P 500	P/E	21.60	EPS (ttm)	5.12	Insider Own	0.10%	Shs Outstand	2.54B	Perf Week	-1.61%
Market Cap	276.95B	Forward P/E	12.98	EPS next Y	8.53	Insider Trans	-21.63%	Shs Float	2.53B	Perf Month	-6.10%
Income	13.03B	PEG	2.65	EPS next Q	1.85	Inst Own	76.60%	Short Float / Ratio	0.77% / 2.68	Perf Quarter	2.80%
Sales	57.87B	P/S	4.79	EPS this Y	17.40%	Inst Trans	0.65%	Short Interest	19.62M	Perf Half Y	0.56%
Book/sh	18.43	P/B	6.01	EPS next Y	22.03%	ROA	12.10%	Target Price	124.42	Perf Year	23.73%
Cash/sh	4.15	P/C	26.66	EPS next 5Y	8.17%	ROE	28.90%	52W Range	83.05 - 119.65	Perf YTD	-0.22%
Dividend	2.92	P/FCF	66.86	EPS past 5Y	25.60%	ROI	20.90%	52W High	-7.47%	Beta	0.36
Dividend %	2.64%	Quick Ratio	1.20	Sales past 5Y	8.10%	Gross Margin	72.80%	52W Low	33.31%	ATR	2.38
Employees	69000	Current Ratio	1.40	Sales Q/Q	-8.90%	Oper. Margin	28.80%	RSI (14)	43.61	Volatility	2.70% 2.05%
Optionable	Yes	Debt/Eq	0.66	EPS Q/Q	-34.70%	Profit Margin	22.50%	Rel Volume	0.89	Prev Close	110.32
Shortable	Yes	LT Debt/Eq	0.60	Earnings	Apr 27 BMO	Payout	55.20%	Avg Volume	7.33M	Price	110.71
Recom	2.00	SMA20	-2.08%	SMA50	-2.57%	SMA200	5.75%	Volume	6,521,823	Change	0.35%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-13-23	Upgrade	Citigroup	Neutral → Buy	$105 → $130
Mar-28-23	Downgrade	Societe Generale	Buy → Hold
Mar-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$120 → $115
Mar-06-23	Initiated	Jefferies	Buy	$125
Feb-22-23	Upgrade	Wolfe Research	Peer Perform → Outperform	$127
Jan-04-23	Upgrade	BofA Securities	Neutral → Buy	$110 → $130
Nov-18-22	Initiated	Credit Suisse	Outperform	$120
Oct-10-22	Upgrade	Guggenheim	Neutral → Buy
Sep-14-22	Upgrade	Berenberg	Hold → Buy	$95 → $100
Jul-06-22	Upgrade	Daiwa Securities	Neutral → Buy	$89 → $102
Jun-06-22	Resumed	SVB Leerink	Outperform	$102
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$80
Dec-17-21	Initiated	Goldman	Buy	$93
Dec-16-21	Initiated	Daiwa Securities	Neutral	$70
Dec-13-21	Downgrade	UBS	Buy → Neutral	$98 → $76
Dec-09-21	Initiated	Wells Fargo	Overweight	$90
Dec-07-21	Downgrade	Guggenheim	Buy → Neutral
Nov-29-21	Downgrade	Citigroup	Buy → Neutral	$105 → $85
Nov-19-21	Initiated	BMO Capital Markets	Market Perform	$91
Nov-01-21	Upgrade	Argus	Hold → Buy	$110

Show Previous Ratings

Jun-09-23 06:49PM	U.S. Chamber of Commerce Challenges Federal Governments New Drug-Price Powers (The Wall Street Journal)
06:35PM	UPDATE 1-US Chamber of Commerce sues over government's drug pricing power (Reuters)
05:07PM	US Chamber of Commerce sues over government's drug pricing power (Reuters)
06:53AM	Four Days Left To Buy Merck & Co., Inc. (NYSE:MRK) Before The Ex-Dividend Date (Simply Wall St.)
Jun-08-23 05:45PM	Merck (MRK) Outpaces Stock Market Gains: What You Should Know (Zacks)
04:13PM	Loading…
04:13PM	15 Healthcare Stocks Billionaires Are Loading Up On (Insider Monkey)
09:00AM	Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
06:45AM	FDA Accepts Application for Mercks KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer (Business Wire)
Jun-07-23 12:45AM	PRESS DIGEST- New York Times business news - June 7 (Reuters)
Jun-06-23 09:00PM	Drug Maker Merck Sues US Gov. Over Inflation Reduction Act (Motley Fool)
05:25PM	Merck Challenges U.S. Governments New Powers to Negotiate Drug Prices (The Wall Street Journal)
04:46PM	Dow Jones Today: Index Higher on Bank Bounce (Investopedia)
03:40PM	Novocure's Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock Tumbles On Remaining Doubts (Benzinga)
03:40PM	Merck sues U.S. government over Medicare drug pricing negotiation (Yahoo Finance Video)
01:11PM	White House says it will win Merck lawsuit, defends Medicare drug negotiations (Reuters)
12:31PM	Loading…
12:31PM	Merck Sues To Stop Medicare Drug Negotiation (Investopedia)
09:23AM	UPDATE 5-Merck sues US government to halt Medicare drug price negotiation (Reuters)
08:44AM	Merck sues US government to halt Medicare drug price negotiation (Reuters)
08:32AM	Merck sues U.S. Department of Health and Human Services (Reuters)
07:20AM	Analyst Report: Merck & Co Inc (Argus Research)
07:05AM	Market Digest: KSS, MRK, OSK, QSR (Argus Research)
06:50AM	U.S. FDA Approves New Indication for Mercks PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients (Business Wire)
06:45AM	Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
Jun-05-23 09:14PM	UPDATE 1-Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data (Reuters)
05:47PM	Moderna and Merck Report Significant Success in Investigational Skin Cancer Therapy, Cuts Risk Of Distant Metastasis Or Death By 65% (Benzinga)
08:00AM	Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA (ACCESSWIRE)
08:00AM	Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data (Reuters)
Jun-03-23 09:00AM	Mercks KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC (Business Wire)
08:00AM	KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma (Business Wire)
Jun-02-23 04:17PM	10 Stocks Jim Cramer Thinks Are Climbing In This Market (Insider Monkey)
06:45AM	Loading…
Jun-01-23 06:45AM	FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) (Business Wire)
May-31-23 06:46PM	New Pfizer RSV Vaccine Rolls Out Into Headwinds of Hesitancy (The Wall Street Journal)
May-25-23 05:00PM	KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (Business Wire)
09:00AM	Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know (Zacks)
04:03AM	14 Best Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
May-24-23 09:33AM	14 Best Healthcare Dividend Stocks to Buy (Insider Monkey)
May-23-23 08:18PM	7 Stocks That Could Be the Next $2 Trillion-Dollar Companies (InvestorPlace)
02:45PM	Merck Announces Third-Quarter 2023 Dividend (Business Wire)
May-22-23 05:30AM	Fed Rate Increases Hit Small Businesses the Hardest (The Wall Street Journal)
May-19-23 11:27AM	3 Undervalued Pharma Stocks to Buy for High Total Returns (InvestorPlace)
May-18-23 07:25AM	25 Most Prescribed Medication in the World (Insider Monkey)
May-17-23 04:47PM	Shhh! 3 Healthcare Stocks Quietly Hitting 52-Week Highs (InvestorPlace)
04:26PM	Fed, labor market concerns showing 'some dents in the armor of the consumer': Strategist (Yahoo Finance Video)
10:21AM	Drugmakers Eye $23 Billion Biotech Argenx Ahead of Key Data (Bloomberg)
May-16-23 10:53AM	Billionaire Ken Fishers Top 15 Dividend Stock Picks (Insider Monkey)
May-15-23 06:45AM	Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting (Business Wire)
May-13-23 11:12AM	10 Great Earnings Reports Jim Cramer is Talking About (Insider Monkey)
May-12-23 06:35AM	The Zacks Analyst Blog Highlights UnitedHealth Group, Merck, Texas Instruments, The TJX Companies and Johnson Controls International (Zacks)
May-11-23 04:14PM	Top Research Reports for UnitedHealth Group, Merck & Texas Instruments (Zacks)
May-09-23 04:09PM	15 Biggest Immunotherapy Companies in the World (Insider Monkey)
May-08-23 02:45PM	Merck Announces Global Grants Program To Improve Access to Quality Health Care in Underserved Communities (ACCESSWIRE)
07:34AM	Technical Assessment: Bearish in the Intermediate-Term (Argus Research)
May-04-23 02:01PM	Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2% (Zacks)
09:00AM	Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock (Zacks)
06:30AM	Moderna beats COVID vaccine sales expectations as deferred revenue rolls in (Reuters)
May-03-23 03:52PM	Insurers Can't Use War Argument: Court Rules in Favor of Merck in $1.4 Billion Cyberattack Coverage Case (Benzinga)
03:00PM	Merck: Supporting Colleagues Working With Cancer (ACCESSWIRE)
06:45AM	Merck to Participate in Bank of America Securities 2023 Healthcare Conference (Business Wire)
May-02-23 03:42PM	Mercks Insurers On the Hook in $1.4 Billion NotPetya Attack, Court Says (The Wall Street Journal)
Apr-28-23 05:59PM	CORRECTED-UPDATE 2-US FDA panel backs restricted use of AstraZeneca's prostate cancer drug (April 28) (Reuters)
05:39PM	CORRECTED-US FDA panel backs AstraZeneca's prostate cancer drug (April 28) (Reuters)
05:30PM	Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (Business Wire)
03:34PM	Merck (MRK) Q1 2023 Earnings Call Transcript (Motley Fool)
12:47PM	Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study (Zacks)
09:17AM	Company News for Apr 28, 2023 (Zacks)
02:56AM	10 Best May Dividend Stocks To Buy (Insider Monkey)
Apr-27-23 04:44PM	FDA Casts Doubt on Merck/AstraZeneca's Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting (Benzinga)
01:10PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
12:44PM	Merck (MRK) Beats on Q1 Earnings and Sales, Ups 2023 View (Zacks)
11:33AM	Why Merck Stock Is Trading Higher Today (Benzinga)
10:00AM	Drugmakers brace for serious headwinds ahead (Yahoo Finance Video)
09:33AM	Drugmakers scout for deals, ramp up research spending (Reuters)
09:26AM	2 of These 3 Stocks Are Lifting the Dow, but 1 Is Holding It Back (Motley Fool)
08:43AM	Merck has strong quarter even as COVID-19 treatment tumble (AP Finance)
07:45AM	Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
06:47AM	Merck & Co posts first-quarter sales beat, raises guidance (Investing.com)
06:38AM	Merck beats first-quarter expectations on Keytruda, Gardasil strength (Reuters)
06:30AM	Merck earnings better-than-expected on Keytruda, Gardasil strength (Reuters)
06:30AM	Merck Announces First-Quarter 2023 Financial Results (Business Wire)
Apr-26-23 08:00AM	Merck Keeps Striking Out on Expanding Its Cancer-Drug Juggernaut (The Wall Street Journal)
Apr-25-23 11:43AM	11 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Apr-21-23 12:16PM	12 Best Pharma Dividend Stocks To Buy in 2023 (Insider Monkey)
10:10AM	Merck (MRK) to Report Q1 Earnings: What's in the Cards? (Zacks)
09:00AM	Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Apr-20-23 10:02AM	Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-19-23 05:45PM	Merck (MRK) Dips More Than Broader Markets: What You Should Know (Zacks)
10:45AM	Is Merck Stock a Screaming Buy After This $11 Billion Acquisition? (Motley Fool)
Apr-18-23 08:00AM	How to Tell Biotechs Likely Winners From Losers (The Wall Street Journal)
03:19AM	Prometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar? (Zacks)
Apr-17-23 03:51PM	Prometheus Biosciences stock soars amid $10.8 billion acquisition deal by Merck (Yahoo Finance Video)
01:28PM	Merck/Prometheus: Big Pharma must swallow bigger premiums (Financial Times)
01:17PM	Moderna stock plunges following mixed analyst reviews of cancer vaccine data (Yahoo Finance)
12:09PM	Why Shares of Prometheus Biosciences Are Soaring Monday (Motley Fool)
10:38AM	Moderna, Merck's Cancer Vaccines Exhibit Positive Outcomes Under Midstage Trial (Benzinga)
10:27AM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
10:06AM	Merck to take $10.3 billion R&D charge for Prometheus deal this year (Reuters)
09:51AM	Midday movers: Charles Schwab, Enphase Energy, Alphabet and more (Investing.com)
09:33AM	Merck agrees to acquire Prometheus Biosciences (Yahoo Finance Video)
06:11AM	Stocks Nudge Higher, Earnings On Deck, Merck Buys Prometheus, Netflix Axes 'Love Is Blind', Charles Schwab Reports - Five Things To Know (TheStreet.com)
06:11AM	Big Bank Earnings Wont Reveal If the Turmoil Is Over. Heres What Will. (Barrons.com)

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Karachun Rita A	Sr. VP Fince-Global Controller	May 04	Option Exercise	65.24	16,824	1,097,552	61,585	May 05 04:54 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	May 04	Option Exercise	118.22	907	107,226	20,207	May 05 05:09 PM
Klobuchar Michael A	EVP - Chief Strategy Officer	May 04	Option Exercise	118.22	885	104,625	19,476	May 05 05:06 PM
LeCointe-Cephas Lisa	SVP Chief Ethics & Com Officer	May 04	Option Exercise	118.22	813	96,113	5,421	May 05 05:01 PM
Zachary Jennifer	EVP, General Counsel	May 04	Sale	117.59	19,141	2,250,834	35,128	May 05 05:13 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 04	Sale	117.53	15,875	1,865,843	45,710	May 05 04:54 PM
MIZELL STEVEN	EVP, Chief HR Officer	May 03	Option Exercise	75.55	52,000	3,928,540	73,085	May 05 05:19 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 03	Option Exercise	117.89	803	94,666	45,363	May 05 04:54 PM
LeCointe-Cephas Lisa	SVP Chief Ethics & Com Officer	May 03	Option Exercise	117.89	689	81,226	4,844	May 05 05:01 PM
MIZELL STEVEN	EVP, Chief HR Officer	May 03	Sale	119.01	53,400	6,355,056	31,685	May 05 05:19 PM
Williams David Michael	EVP,Chief Info&Digital Officer	May 02	Option Exercise	56.04	6,035	338,201	18,568	May 03 04:29 PM
Williams David Michael	EVP,Chief Info&Digital Officer	May 02	Sale	116.82	7,509	877,222	11,059	May 03 04:29 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	May 01	Option Exercise	56.04	75,436	4,227,433	229,929	May 02 11:37 AM
Li Dean Y	Executive VP & President, MRL	May 01	Option Exercise	115.47	1,062	122,629	20,995	May 03 04:10 PM
Karachun Rita A	Sr. VP Fince-Global Controller	May 01	Option Exercise	115.47	930	107,387	44,879	May 03 04:24 PM
Litchfield Caroline	EVP & CFO	May 01	Option Exercise	115.47	866	99,997	32,118	May 03 04:07 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	May 01	Option Exercise	115.47	866	99,997	19,727	May 03 03:54 PM
Klobuchar Michael A	EVP - Chief Strategy Officer	May 01	Option Exercise	115.47	866	99,997	18,901	May 03 03:00 PM
LeCointe-Cephas Lisa	SVP Chief Ethics & Com Officer	May 01	Option Exercise	115.47	643	74,247	4,376	May 03 03:11 PM
Williams David Michael	EVP,Chief Info&Digital Officer	May 01	Option Exercise	115.47	577	66,626	12,731	May 03 04:29 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	May 01	Sale	116.03	75,436	8,752,749	154,493	May 02 11:37 AM
Davis Robert M	Chairman, CEO & President	Apr 28	Option Exercise	56.04	143,329	8,032,157	415,146	Apr 28 05:15 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Apr 28	Option Exercise	62.07	66,163	4,106,737	220,656	May 02 11:37 AM
Davis Robert M	Chairman, CEO & President	Apr 28	Sale	114.93	143,329	16,472,845	271,817	Apr 28 05:15 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Apr 28	Sale	115.00	66,163	7,608,844	154,493	May 02 11:37 AM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Apr 13	Option Exercise	59.02	134,055	7,911,405	134,055	Apr 14 04:34 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Apr 13	Sale	115.07	134,055	15,425,068	0	Apr 14 04:34 PM
Romanelli Joseph	President, Human Health Int?l	Feb 15	Sale	108.22	5,000	541,100	20,284	Feb 16 11:58 AM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 13	Sale	109.10	1,815	198,017	33,085	Feb 14 10:03 AM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 10	Option Exercise	106.72	1,205	128,598	12,505	Feb 13 04:17 PM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 09	Sale	107.00	5,000	535,006	34,900	Feb 10 11:28 AM
MIZELL STEVEN	EVP, Chief HR Officer	Feb 06	Sale	104.25	4,436	462,473	39,900	Feb 08 10:27 AM
Zachary Jennifer	EVP, General Counsel	Feb 03	Option Exercise	56.04	75,436	4,227,433	129,356	Feb 06 04:21 PM
Zachary Jennifer	EVP, General Counsel	Feb 03	Sale	103.17	75,436	7,782,762	53,920	Feb 06 04:21 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Jan 09	Option Exercise	53.06	83,994	4,456,722	113,494	Jan 11 04:22 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Jan 09	Sale	112.29	83,994	9,431,915	29,500	Jan 11 04:22 PM
MIZELL STEVEN	EVP, Chief HR Officer	Nov 10	Option Exercise	0.00	15,000	0	47,144	Nov 10 05:01 PM
MIZELL STEVEN	EVP, Chief HR Officer	Nov 10	Sale	101.42	15,000	1,521,278	32,144	Nov 10 05:01 PM
Davis Robert M	CEO & President	Nov 09	Option Exercise	0.00	167,613	0	415,206	Nov 10 04:42 PM
Davis Robert M	CEO & President	Nov 09	Sale	102.44	167,613	17,169,840	247,593	Nov 10 04:42 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Nov 09	Sale	103.21	1,795	185,262	16,731	Nov 10 04:44 PM
MIZELL STEVEN	EVP, Chief HR Officer	Nov 08	Option Exercise	0.00	20,000	0	52,144	Nov 10 05:01 PM
MIZELL STEVEN	EVP, Chief HR Officer	Nov 08	Sale	101.00	20,000	2,020,000	32,144	Nov 10 05:01 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Nov 07	Option Exercise	0.00	52,743	0	64,087	Nov 07 04:09 PM
FRAZIER KENNETH C	Executive Chair	Nov 07	Option Exercise	0.00	235,769	0	936,422	Nov 08 04:56 PM
FRAZIER KENNETH C	Executive Chair	Nov 07	Sale	99.55	235,769	23,471,433	700,653	Nov 08 04:56 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Nov 07	Sale	99.47	45,561	4,531,980	18,526	Nov 07 04:09 PM
FRAZIER KENNETH C	Executive Chair	Nov 04	Option Exercise	0.00	235,000	0	935,653	Nov 07 04:06 PM
FRAZIER KENNETH C	Executive Chair	Nov 04	Sale	98.61	235,000	23,174,230	700,653	Nov 07 04:06 PM
FRAZIER KENNETH C	Executive Chair	Nov 03	Option Exercise	0.00	235,000	0	935,653	Nov 07 04:06 PM
FRAZIER KENNETH C	Executive Chair	Nov 03	Sale	98.71	235,000	23,197,888	700,653	Nov 07 04:06 PM
FRAZIER KENNETH C	Executive Chair	Nov 02	Option Exercise	0.00	300,000	0	1,000,653	Nov 03 04:06 PM
FRAZIER KENNETH C	Executive Chair	Nov 02	Sale	99.91	300,000	29,971,843	700,653	Nov 03 04:06 PM
FRAZIER KENNETH C	Executive Chair	Nov 01	Option Exercise	0.00	300,000	0	1,006,283	Nov 03 04:06 PM
FRAZIER KENNETH C	Executive Chair	Nov 01	Sale	99.81	300,000	29,942,864	706,283	Nov 03 04:06 PM
FRAZIER KENNETH C	Executive Chair	Oct 31	Option Exercise	0.00	300,000	0	1,006,283	Nov 01 04:38 PM
FRAZIER KENNETH C	Executive Chair	Oct 31	Sale	100.75	300,000	30,224,092	706,283	Nov 01 04:38 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Oct 30	Option Exercise	100.77	913	92,003	11,794	Nov 01 04:30 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Oct 28	Option Exercise	0.00	164,557	0	301,534	Nov 01 05:04 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Oct 28	Option Exercise	0.00	100,292	0	145,900	Nov 01 05:07 PM
Zachary Jennifer	EVP, General Counsel	Oct 28	Option Exercise	0.00	148,647	0	203,295	Nov 01 04:28 PM
Karachun Rita A	Sr. VP Fince-Global Controller	Oct 28	Option Exercise	0.00	31,997	0	73,100	Nov 01 04:36 PM
MIZELL STEVEN	EVP, Chief HR Officer	Oct 28	Option Exercise	0.00	17,000	0	57,144	Nov 01 04:33 PM
FRAZIER KENNETH C	Executive Chair	Oct 28	Option Exercise	0.00	567,084	0	1,273,367	Nov 01 04:38 PM
FRAZIER KENNETH C	Executive Chair	Oct 28	Sale	100.28	567,084	56,866,272	706,283	Nov 01 04:38 PM
DeLuca Richard R.	EVP&Pres, Merck Animal Heallth	Oct 28	Sale	100.26	164,557	16,499,094	136,977	Nov 01 05:04 PM
Zachary Jennifer	EVP, General Counsel	Oct 28	Sale	99.38	165,255	16,422,893	38,040	Nov 01 04:28 PM
Chattopadhyay Sanat	Exe V-P & Pres. MMD	Oct 28	Sale	100.10	100,292	10,039,380	45,608	Nov 01 05:07 PM
Karachun Rita A	Sr. VP Fince-Global Controller	Oct 28	Sale	100.34	31,997	3,210,685	41,103	Nov 01 04:36 PM
MIZELL STEVEN	EVP, Chief HR Officer	Oct 28	Sale	99.63	25,000	2,490,720	32,144	Nov 01 04:33 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Oct 28	Sale	100.21	3,633	364,065	10,881	Nov 01 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK | Merck & Co., Inc.

Upgrade your FINVIZ experience